JP2017001966A - Blood triglyceride elevation-inhibiting composition - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide blood triglyceride elevation-inhibiting compositions in which a blood triglyceride elevation inhibitory effect is improved dramatically.SOLUTION: A blood triglyceride elevation-inhibiting composition is characterized by containing as an active ingredient indigestible dextrin, and at least one component selected from the group consisting of pine bark extract, processed young leaves of Hordeum vulgare, collagen, pectin, tannin, alanine, valine, vitamin A, vitamin B1, niacin, sodium pantothenate, vitamin E, and a selenium compound.SELECTED DRAWING: Figure 1

Description

  The present invention relates to a blood neutral fat increase inhibitory composition, and more particularly, to a blood neutral fat increase inhibitory composition comprising an indigestible dextrin and a specific other component as active ingredients.

  Indigestible dextrins are known to have various functions for adjusting the body condition, and as one of them, blood neutral fat elevation-inhibiting action is known. However, it cannot be said that the single effect is sufficient.

  On the other hand, as for the function of indigestible dextrin, for example, an IgA secretion promoter containing indigestible dextrin as an active ingredient (see Patent Document 1) or for patients with renal failure having indigestible dextrin as an active ingredient A blood cresol reducing agent (see Patent Document 2) has been proposed.

JP 2014-152125 A JP 2014-148467 A

  An object of the present invention is to provide a blood neutral fat increase-inhibiting composition that has dramatically improved blood neutral fat increase-inhibiting action.

  The present inventors have intensively investigated and studied the effect of indigestible dextrin on blood neutral fat elevation, and by combining specific ingredients with indigestible dextrin, the blood neutral fat elevation inhibitory action has jumped. The present invention has been found to be able to be improved. In other words, by combining an ingredient with little or no effect on blood triglyceride inhibition and low-digestibility dextrin, the blood triglyceride rise is higher than that of non-digestible dextrin alone. It was found that the inhibitory action can be improved dramatically.

  That is, the present invention relates to an indigestible dextrin, a pine bark extract, a barley young leaf processed product, collagen, pectin, tannin, alanine, valine, vitamin A, vitamin B1, niacin, sodium pantothenate, vitamin E, and selenium compound. The present invention relates to a blood neutral fat increase-suppressing composition comprising as an active ingredient at least one component selected from the group consisting of:

  The blood neutral fat elevation inhibiting composition of the present invention may be obtained by adding an active ingredient.

In the blood neutral fat increase inhibiting composition of the present invention, the blending mass ratio of the indigestible dextrin and other active ingredients is preferably in the range of 0.5: 1 to 70: 1.
Moreover, it is preferable that the blood neutral fat rise suppression composition of this invention is a tablet, a capsule, a powder agent, a granule, or a liquid agent.

  The present invention also relates to a method for inhibiting blood triglyceride elevation (excluding medical practice), characterized in that the composition for inhibiting blood triglyceride elevation of the present invention is ingested.

  According to the blood neutral fat increase inhibitory composition of the present invention, the blood neutral fat increase suppressive action can be dramatically improved as compared with the case of the indigestible dextrin alone.

It is a figure which shows the triglyceride (TG) density | concentration secreted after absorption to the Caco-2 monolayer film at the time of applying the blood triglyceride rise suppression composition of this invention, and is a pine bark extract with indigestible dextrin The result when using is shown. It is a figure which shows the secreted triglyceride (TG) density | concentration after absorption to the Caco-2 monolayer film at the time of applying the blood triglyceride rise suppression composition of this invention, and barley young leaves and collagen with indigestible dextrin The results when pectin and tannic acid are used are shown. It is a figure which shows the secreted triglyceride (TG) density | concentration after absorption to the Caco-2 monolayer film at the time of applying the blood triglyceride rise suppression composition of this invention, and used alanine with the indigestible dextrin. The result of the case is shown. It is a figure which shows the triglyceride (TG) density | concentration secreted after absorption to the Caco-2 monolayer film at the time of applying the blood triglyceride rise suppression composition of this invention, and used valine with the indigestible dextrin. The result of the case is shown. It is a figure which shows the secreted triglyceride (TG) density | concentration after absorption to the Caco-2 monolayer film at the time of applying the blood neutral fat rise suppression composition of this invention, and uses vitamin A with indigestible dextrin The result is shown. It is a figure which shows the triglyceride (TG) density | concentration secreted after absorption to the Caco-2 monolayer film at the time of applying the blood triglyceride rise suppression composition of this invention, vitamin B1, niacin with indigestible dextrin The result at the time of using sodium pantothenate is shown. It is a figure which shows the secreted triglyceride (TG) density | concentration after absorption to the Caco-2 monolayer film at the time of applying the blood neutral fat rise suppression composition of this invention, and uses vitamin E with indigestible dextrin The result is shown. It is a figure which shows the triglyceride (TG) density | concentration secreted after absorption to the Caco-2 monolayer film at the time of applying the blood triglyceride rise suppression composition of this invention, and a serine compound (sublimation with an indigestible dextrin). The result when using sodium selenate) is shown.

  The composition for inhibiting blood triglyceride elevation according to the present invention comprises an indigestible dextrin, a pine bark extract, a processed barley leaf product, collagen, pectin, tannin, alanine, valine, vitamin A, vitamin B1, niacin, pantothenic acid It contains at least one component selected from the group consisting of sodium, vitamin E, and a selenium compound (hereinafter sometimes referred to as other components) as an active ingredient.

[Indigestible dextrin]
The indigestible dextrin, which is an active ingredient of the blood neutral fat elevation inhibitory composition of the present invention, is an indigestible polysaccharide that is difficult to be hydrolyzed by human digestive enzymes (amylases). After hydrolysis, it can be obtained by hydrolysis with amylase and purification of components that are difficult to hydrolyze. This indigestible dextrin is commercially available in the form of powder, fine granules, granules and the like, and these commercially available products can be used. Moreover, since indigestible dextrin is water-soluble, you may use the thing of the form of aqueous solution.

[Other ingredients]
(Pine bark extract)
Examples of pine as a raw material for pine bark extract include French maritime pine (Pinus Martina), larch, black pine, Japanese red pine, etc. Among them, French maritime pine (Pinus) rich in proanthocyanidins. Martina) is preferred. The extract can be obtained by extraction using an appropriate solvent. As the solvent, for example, water (hot water, hot water), ethanol, or hydrous ethanol can be used. In addition to proanthocyanidins, the extract contains oligomeric proanthocyanidins at a high concentration, and for example, those containing 20% by mass or more of oligomeric proanthocyanidins with respect to the dry mass of the extract are preferable.

(Processed barley leaves)
As barley used as a raw material for the processed barley young leaves, Nijo barley, Rojo barley and the like can be used. As the processed barley leaves, processed products such as pulverized barley, squeezed juice, and extract can be used. Examples of the pulverized product include powder and granules. The juice or extract may be liquid, but can also be used as a paste or dry powder. The extract can be obtained by extraction using an appropriate solvent. As the solvent, for example, water (hot water, hot water), ethanol, or hydrous ethanol can be used.

(collagen)
The collagen may be animal-derived collagen or synthetic collagen. In addition to collagen protein, collagen peptide obtained by hydrolyzing collagen protein, or collagen molecule treated with protease, telopeptide moiety Atelocollagen is removed. As animal-derived collagen, collagen derived from fish is particularly preferable. Although it does not restrict | limit especially as an average molecular weight (weight average molecular weight) of collagen, For example, it is preferable that it is 500-100000, and it is more preferable that it is 1000-50000.

(Pectin)
The pectin may be a plant-derived pectin or a synthetic pectin. Examples of plant-derived pectin include extracts from fruits and vegetables such as apples and citrus fruits. Pectin is classified into HM pectin having a high degree of esterification and LM pectin having a low degree of esterification, and any pectin may be used. Moreover, as pectin, the pectin marketed as a gelatinizer, a thickener, etc. can be used.

(Tannin)
Tannins may be hydrolyzable tannins or condensed tannins, for example, obtained from oyster fruit, chestnut astringent skin, pentaple, tamarind seed coat, cod powder, gallic and mimosa bark. Mention may be made of extracts. Alternatively, tannic acid (C ₇₆ H ₅₂ O ₄₆ ) can be used.

  It is preferable that the blood triglyceride elevation inhibitory composition of the present invention is a blood triglyceride elevation inhibitor used for blood triglyceride elevation inhibition. Such a blood neutral fat elevation inhibitor contains indigestible dextrin and other prescribed components, and can be distinguished from other products as a product in that it is used to suppress blood neutral fat elevation. If there is no particular limitation, for example, the body of the product according to the present invention, packaging, instructions, or promotional materials that indicate that there is a function of suppressing blood neutral fat elevation It is included in the scope of the present invention. For example, so-called health foods such as pharmaceuticals (including quasi-drugs), functional foods for which the indication of efficacy has been approved by specified organizations such as foods for specified health use, functional nutritional foods, functional foods, etc. Can be mentioned. In so-called health foods, "Suppresses the increase in neutral fat", "For those who are concerned about neutral fat", "Suppress the absorption of fat", "For those who have higher neutral fat", etc. Things can be illustrated. These health foods may be taken separately from the meal, but are preferably taken at the time of the meal. For example, it is preferably taken between 1 hour before the meal and 1 hour after the meal. It is more preferable to take between 5 hours and 0.5 hours after meal, and it is more preferable to take from 0.5 hours before meal to the start of meal or during meal.

  Examples of the form of the blood neutral fat elevation inhibiting composition of the present invention include tablets, capsules, powders, granules, liquids, granules, rods, plates, blocks, solids, Examples include round agents, paste agents, cream agents, caplet agents, gel agents, chewable agents, stick agents, and the like. Among these, the forms of tablets, capsules, powders, granules, and liquids are particularly preferable. Specifically, supplements, container-packed beverages filled in PET bottles, cans, bottles, etc., instant powder beverages and instant granule beverages for dissolving and drinking in water (hot water), milk, fruit juice, green juice, etc. Can be illustrated. These are preferable in that they can be easily taken at the time of eating and the like, and can enhance palatability.

  The contents of the indigestible dextrin and other components (active ingredients) in the blood neutral fat elevation inhibiting composition of the present invention may be appropriately contained within the range where the effects are exerted.

  Generally, when the blood neutral fat elevation-suppressing composition of the present invention is a pharmaceutical product or a supplement (tablet, capsule), the active ingredient is contained in an amount of 0.01 to 100% by mass in terms of dry mass. It is preferable that 0.1 to 85% by mass is included, and 0.5 to 70% by mass is further preferable.

  When the blood neutral fat elevation-suppressing composition of the present invention is a packaged beverage (liquid), the active ingredient is preferably contained in an amount of 0.1 to 10% by mass in terms of dry mass. More preferably, it is contained in an amount of 3 to 6% by mass, and more preferably 0.5 to 4% by mass.

  Moreover, when the blood neutral fat rise suppression composition of this invention is an instant powdered drink (powder) and an instant granule drink (granule), an active ingredient is 10-100 mass% of the whole in conversion of dry mass. It is preferably contained, more preferably 50 to 100% by mass, and even more preferably 80 to 100% by mass.

  In order to exhibit the effect of the present invention particularly effectively, the active ingredient should be contained in an amount of 80% by mass or more of the whole blood neutral fat increase inhibiting composition of the present invention (excluding water) in terms of dry mass. Preferably, it is more preferably 90% by mass or more, more preferably 95% by mass or more, and particularly preferably 100%.

  The amount of intake of the composition for inhibiting blood triglyceride elevation of the present invention is not particularly limited, but from the viewpoint of exerting the effects of the present invention more remarkably, the intake amount of the active ingredient per day is 500 mg / day or more. Ingestion is preferable, more preferably 1 g / day or more, more preferably 2 g / day or more, and more preferably 4 g / day or more. It is particularly preferable to do this.

  The composition for suppressing blood triglyceride elevation according to the present invention is divided into one container or, for example, a plurality of containers such as 2 to 3 so that the daily intake becomes the above-mentioned intake amount. Can be accommodated.

  Further, the blood triglyceride increase inhibitory composition of the present invention may be taken separately from the meal, but it can particularly effectively suppress the transient increase in blood triglyceride after the meal. Preferably taken during meals, for example, preferably taken between 1 hour before meal and 1 hour after meal, taken between 0.5 hour before meal and 0.5 hour after meal More preferably, it is more preferably taken from 0.5 hours before meal to the start of meal or during meal.

  The blending mass ratio of the indigestible dextrin and other components is preferably in the range of 0.5: 1 to 70: 1 and in the range of 0.75: 1 to 60: 1 in terms of dry mass. Is more preferably in the range of 1: 1 to 60: 1, and particularly preferably in the range of 1: 1 to 50: 1. The effects of the present invention can be more effectively exhibited when the blending ratio of the indigestible dextrin and other components is within the above range.

  The blood neutral fat elevation-suppressing composition of the present invention can be produced by a known formulation method by adding components other than the active ingredients that are acceptable for oral use, if necessary.

  In addition, as the blood neutral fat increase inhibitory composition of the present invention, the blood neutrality obtained by adding an active ingredient to foods in addition to the blood neutral fat increase inhibitory composition containing the active ingredient Examples thereof include fat elevation-inhibiting compositions (foods that inhibit blood neutral fat elevation), such as foods having an increased content of the active ingredient of the present invention as compared to ordinary foods (including natural foods) The foodstuff which added the active ingredient with respect to the foodstuff which does not normally contain the active ingredient of this invention can be mentioned. Moreover, as a blood neutral fat rise inhibitory composition of this invention, the fat content is 10 mass% or more, Preferably it is 20 mass% or more from the point by which the effect of this invention is exhibited more effectively. In contrast, a high-fat food that suppresses blood neutral fat elevation and is obtained by adding an active ingredient is preferable. For the addition of the active ingredients, the respective ingredients may be added separately, may be added simultaneously, or may be added together with other ingredients other than the active ingredients.

  Examples of the food for suppressing blood neutral fat elevation of the present invention include, for example, carbonated drinks, nutrition drinks, fruit drinks, lactic acid drinks, smoothies, green juices, etc .; Ice cream, ice sherbet, shaved ice and other frozen desserts; buckwheat, udon , Harusame, Chinese noodles, instant noodles and other noodles; sweets such as candy, candy, gum, chocolate, tablet candy, snack confectionery, biscuits, jelly, jam, cream, baked confectionery, bread; marine products such as kamaboko, ham, sausage -Livestock processed foods; Dairy products such as processed milk, fermented milk, yogurt; salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, dressing and other fats and processed foods; sauces, soy sauce and other seasonings; curry, Stew, oyakodon, porridge, rice cooked rice, Chinese rice bowl, bonito, tempura bowl, beef bowl, hayashi rice, omelet rice, oden Mabodofu, dumplings, Shumai, hamburger, meatballs, various sources, such as retort pouch foods such as various types of soup can be mentioned.

  The method for inhibiting blood neutral fat elevation according to the present invention is characterized by ingesting the blood neutral fat elevation inhibiting composition of the present invention described above, but does not include medical practice. The blood triglyceride elevation-suppressing composition of the present invention may be ingested separately from meals, but since it can particularly effectively inhibit the transient blood triglyceride rise after meals, For example, preferably 1 hour before meal to 1 hour after meal, more preferably 0.5 hour before meal to 0.5 hour after meal Further, it is more preferable to take from 0.5 hours before meal to the start of meal or during meal. As a method of the present invention, for example, in a restaurant such as a restaurant, by providing the blood neutral fat increase-suppressing composition of the present invention together with a high-fat food, a method for suppressing blood neutral fat increase is provided. Can be mentioned.

Hereinafter, the present invention will be described based on examples.
[Example 1]
Neutral fat absorption inhibition (inhibition of blood neutral fat elevation) was evaluated by human colon cancer-derived cell Caco-2 monolayer absorption and secretion test. Caco-2 cells are known to differentiate like intestinal epithelium by culture, and intestinal absorptivity can be evaluated by measuring the amount of substance permeated through the Caco-2 monolayer.

1. Preparation of Samples Adjusted to 0.2 mM lysophosphatidylcholine, 0.1 mM oleic acid, 0.1 mM 2-monooleolyglycol, and 2 mM sodium taurooxycholate, and sonicated to prepare 300-500 nm micelles.

  The above prepared micelles and test substances (indigestible dextrin alone or indigestible dextrin + other components shown in Table 1) were added to DMEM to adjust the final concentration.

2. Caco-2 monolayer absorption and secretion test 100 μL of the sample was added to the insert well of the Caco-2 monolayer, and held in a 37 ° C., 5% CO ₂ incubator. After 24 hours, 600 μL of the solution on the basement membrane side was collected, 200 μL of CHCl ₃ : MeOH = 2: 1 was added, and centrifugation was performed after vortexing. The lower layer (organic layer) was collected, and 200 μL of CHCl ₃ : MeOH = 2: 1 was added again, followed by centrifugation after vortexing. The lower layer (organic layer) was collected, and the organic layer was dried. 20 μL of 2-propanol was added, and triglyceride (TG) was measured. The Wako kit (Triglyceride E-Test Wako) was used for TG measurement.

  The results are shown in Table 1 and FIGS. In each graph in the figure, “−” indicates no addition and “+” indicates a single addition of 200 μg / mL indigestible dextrin for the control (difficulty). Moreover, about what the other component was displayed, "-++" shows addition of the other component independently, and "++" shows 200 microgram / mL indigestible dextrin + addition of other components.

For the indigestible dextrin, commercially available indigestible dextrin powder was used.
For barley young leaves, dry pulverized powder was used.
As for pine bark, a hot water extract (dry powder) of bark of French coastal pine was used.
For sweet candy young leaves, dry pulverized powder was used.

  As shown in Table 1 and FIGS. 1 to 8, the amount of fat passing through the Caco-2 monolayer synergistically decreased by combining the indigestible dextrin and the specific other component of the present invention. Therefore, it can be seen that the increase in blood neutral fat according to the present invention can effectively suppress the increase in blood neutral fat.

[Example 2] (Manufacture of tablets)
Each component was mixed in the ratio shown below, and tableting was performed with a tableting machine.

Formulation composition Composition (mg)
Indigestible dextrin 135
Barley young powder 150
Excipient 120
Vitamin B1 15
Citric anhydride 15
Alanine 10
Valine 10

  For example, by taking several tablets per day, it is expected that the effect of suppressing blood neutral fat elevation can be obtained.

[Example 3] (Manufacture of capsules)
Each component was mixed in the ratio shown below, and it was set as the granule according to the conventional method, The capsule was filled with 250 mg of the granule, and the capsule was prepared.
Ingredients Weight parts Indigestible dextrin 15
Pine bark extract 1
Collagen 1
Vitamin E 0.1
Excipient 5

  For example, by taking several capsules per day, it is expected that the effect of suppressing blood neutral fat elevation can be obtained.

[Example 4] (Production of granules)
Each component was mixed at the ratio shown below to obtain granules according to a conventional method, and 800 mg of the granules were packaged in an aluminum stick.
Ingredients Weight parts Indigestible dextrin 15
Barley Wakaba 1
Excipient 5
Citric anhydride 0.1
Tannic acid 0.01

  It is expected that the effect of suppressing blood neutral fat elevation can be obtained by taking this granule, for example, several bags per day.

[Example 5] (Manufacture of solution)
The container was filled with 1 part by weight of pine bark extract, 5 parts by weight of barley young leaf powder, 3 parts by weight of indigestible dextrin hydrolyzed collagen, appropriate amount of vitamin C, and 200 ml of water, and sealed to prepare a liquid.

  The composition for suppressing blood triglyceride elevation according to the present invention has an effect of suppressing the increase of triglyceride in blood, and therefore has high industrial utility.

Claims (5)

  Selected from the group consisting of indigestible dextrin, pine bark extract, processed barley young leaves, collagen, pectin, tannin, alanine, valine, vitamin A, vitamin B1, niacin, sodium pantothenate, vitamin E, and selenium compound A composition for suppressing an increase in blood neutral fat, comprising at least one component as an active ingredient.   The composition for suppressing blood triglyceride elevation according to claim 1, obtained by adding an active ingredient.   The composition for inhibiting the increase in blood neutral fat according to claim 1 or 2, wherein the blending mass ratio of the indigestible dextrin and other active ingredients is in the range of 0.5: 1 to 70: 1.   The composition for inhibiting blood neutral fat elevation according to any one of claims 1 to 3, wherein the composition is a tablet, capsule, powder, granule, or liquid.   A method for suppressing blood triglyceride elevation, wherein the composition for inhibiting blood triglyceride elevation according to any one of claims 1 to 4 is ingested (except for medical practice).